The Pro-Seq technology links molecules prior to sequencing to enable detection of low-frequency variants, and could be complementary to Boreal's OnTarget technology.
Investigators using droplet digital PCR methods are following cell-free tumor DNA in the blood, looking for patterns coinciding with immunotherapy treatment outcomes.
The company will work with USC researchers in a year-long study aimed at assessing the clinical utility of EntroGen's PCR-based liquid biopsy test for EGFR mutations.
The company said that it has had interest so far in its focused Avenio kits as well as larger panels for surveillance and monitoring.
Researchers demonstrated the feasibility of finding multiple myeloma mutations with a new circulating tumor DNA sequencing method known as LB-Seq.
The money will fund a new plan to sequence tumor DNA from more than 1 million cancer patients. The firm also announced a new JV in Asia, the Middle East, and Africa.
Grail plans to enroll up to 120,000 women who have been screened via mammogram, to train and validate its NGS-based early detection cancer test.
At the AACR annual meeting earlier this month, attendees discussed challenges in demonstrating analytical and clinical validity appropriately for liquid biopsy tests.
Results of a new study show that patients guided to targeted therapy based on ctDNA get the same benefits as those who got tissue-based tests in initial clinical trials.
With new research and commercial test launches, clincians anticipate exciting new tools but judging quality and utility has become challenging.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.